MDCO Scores in SOLO-1 Trial – Analyst Blog

By | December 24, 2012
0 Comment

The Medicines Company ( MDCO ) recently received good news with the company announcing positive results on its phase III antibiotic candidate, oritavancin.

Read More:
MDCO Scores in SOLO-1 Trial – Analyst Blog

Related posts:

  1. The Medicines Co. Acquires Incline – Analyst Blog
  2. Intercept Pharma Liver-Disease Drug Scores In Trial
  3. FB Embroiled in Trademark Trial – Analyst Blog
  4. Phase III Data on Novartis’ RLX030 – Analyst Blog